These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7222858)

  • 1. [Monitoring of heparin therapy with activated recalcification time].
    Lutze G; Schlote A; Urbahn H
    Z Gesamte Inn Med; 1981 Feb; 36(4):102-6. PubMed ID: 7222858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].
    Lutze G; Presser HJ; Urbahn H
    Z Gesamte Inn Med; 1989 Apr; 44(8):235-40. PubMed ID: 2662657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS; Morris MW; Davey FR
    Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
    Lang M; Fey MF; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
    Hürzeler C; von Felten A
    Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring of heparin therapy using thrombin time and activated partial thromboplastin time--a comparison].
    Osterwalder J
    Schweiz Med Wochenschr; 1987 Apr; 117(14):539-40. PubMed ID: 3576165
    [No Abstract]   [Full Text] [Related]  

  • 7. [Modification of the global coagulation tests for the dog. Significance for the monitoring of heparin therapy].
    Mischke R; Nolte I
    Tierarztl Prax; 1991 Oct; 19(5):561-6. PubMed ID: 1759273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of a new method of therapeutic control of heparin].
    Pizzuto J; Garcia S; de la Paz Reyna M; Morales MR; Avilés A; Zavala B; Ponce L; Gaos C
    Arch Inst Cardiol Mex; 1978; 48(2):373-86. PubMed ID: 666447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
    Bhargava AS; Heinick J; Schöbel C; Günzel P
    Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin time dilution test: a simple method for the control of heparin therapy.
    Pizzuto J; García-Méndez S; de-la-Paz Reyna M; Morales MR; Avilés A; Zavala B; Gaos C
    Thromb Haemost; 1979 Dec; 42(4):1276-85. PubMed ID: 542933
    [No Abstract]   [Full Text] [Related]  

  • 12. Problems by using whole blood in heparin measurements.
    Talstad I
    Thromb Haemost; 1982 Apr; 47(2):177-81. PubMed ID: 7101239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.
    Douglas AD; Jefferis J; Sharma R; Parker R; Handa A; Chantler J
    Angiology; 2009; 60(3):358-61. PubMed ID: 19398428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Laboratory control of anticoagulant treatments (author's transl)].
    Samama M; Conard J; Horellou MH
    J Mal Vasc; 1981; 6(4):257-61. PubMed ID: 7320641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
    Bounameaux H; Marbet GA; Lämmle B; Eichlisberger R; Duckert F
    Am J Clin Pathol; 1980 Jul; 74(1):68-73. PubMed ID: 7395817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Activated thromboplastin time, plasma heparin and plasma fibrinogen using the Fibrintimer 10].
    Khayat MC; Laforet F; Khayat A; Derlon A; Lequerrec A; Thomas M
    Ann Biol Clin (Paris); 1988; 46(8):696-700. PubMed ID: 3218791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative multicenter study of a rabbit high-sensitivity thromboplastin and a recombinant thromboplastin with synthetic phospholipids].
    Martínez-Brotóns F; Borrell M; Fontcuberta J; Batlle J; López F; Páramo JA; Ribera C; Rocha E; Vicente V; Zuazu I
    Sangre (Barc); 1994 Aug; 39(4):245-51. PubMed ID: 7985052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
    Francis JL; Howard C
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The kaolin-activated recalcification test in the screening of coagulation disorders and in the control of anticoagulant therapy].
    Barberi G; Fiocca S
    Quad Sclavo Diagn; 1977 Jun; 13(2):167-75. PubMed ID: 594303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of heparin therapy].
    Camici M; Evangelisti L
    Minerva Med; 1993 Oct; 84(10):507-9. PubMed ID: 8247304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.